Center for Breakthrough Medicines is partnering with Discovery Labs to speed up its plans to build the capacity to manufacture a substantial number of cell therapy products at its King of Prussia headquarters, writes Tyler Patchen for Endpoints News.

The planning, which was previously slated for 2025, has started on the manufacturing suites and the required supporting infrastructure. When the facility is completed, the site will be able to manufacture about 10,000 batches of product per year.

The new, one-million-square-foot cell therapy extension will have 90,000 square feet of manufacturing space along with offices and warehouse space. The costs to build the facility will be in the hundreds of millions, according to John Lee, VP and head of cell therapy at CBM.

“We have leveraged knowledge gained from our current build and forward engineered the facility to enable modularity and to increase efficiency to better serve clients (and patients),” said Lee. “Modular suite design across approximately 90,000 square feet of Grade-B GMP space will enable agility and flexibility to accommodate an array of processes.”

The site is expected to come online early next year.

Read more about the Center for Breakthrough Medicines and Discovery Labs in King of Prussia in Endpoints News.